{"id":"W4401897346","doi":"10.1016/s2152-2650(24)00705-5","title":"Pelabresib Plus Ruxolitinib Combination Therapy in JAK Inhibitor-Naïve Patients With Myelofibrosis in the Phase 3 MANIFEST-2 Study: Preliminary Evidence of Bone Marrow Recovery","year":2024,"lang":"en","type":"article","venue":"Clinical Lymphoma Myeloma & Leukemia","topic":"Myeloproliferative Neoplasms: Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Ruxolitinib; Myelofibrosis; Internal medicine; Oncology; Bone marrow","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001379224,0.0008638223,0.00184196,0.000300492,0.0002816619,0.001037907,0.0005616174,0.0006860188,0.002364436],"category_scores_gemma":[0.0008715604,0.0003344641,0.001143397,0.000305762,0.0004264082,0.0007894683,0.0002383896,0.00207624,0.0005081022],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005420989,"about_ca_system_score_gemma":0.0007767092,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000663397,"about_ca_topic_score_gemma":0.002470462,"domain_scores_codex":[0.9996341,0.0001982504,0.00001802695,0.00004213686,0.00003101361,0.00007649927],"domain_scores_gemma":[0.9995356,0.0001055679,0.0001022809,0.00004083988,0.000024329,0.0001915501],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7000397,0.02305451,0.01766071,0.001081285,0.002921658,0.0004540656,0.0002648974,0.002385278,0.02287748,0.0003838665,0.005797754,0.2230788],"study_design_scores_gemma":[0.5919579,0.3304502,0.06453659,0.0001247747,0.001536789,0.0007999039,0.0001316134,0.001745326,0.00264647,0.0003601614,0.005656382,0.00005384884],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.990341,0.005593393,0.0002700941,0.000586007,0.0001031575,0.0005430495,0.000704376,0.0000852793,0.001773741],"genre_scores_gemma":[0.9930555,0.00264306,0.0007116379,0.0006411051,0.0001319041,0.0004168754,0.001254306,0.00001589854,0.001129736],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002364436,"threshold_uncertainty_score":0.007909775,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04308279592004458,"score_gpt":0.353121807247851,"score_spread":0.3100390113278064,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}